JD HEALTH
06618
BIDU-SW
09888
JD-SW
09618
ALI HEALTH
00241
BEKE-W
02423
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | ---- | 17.67%2.26B | ---- | 33.58%1.92B | ---- | 20.82%1.44B | ---- | 11.27%1.19B | ---- | 47.33%1.07B |
Profit adjustment | ||||||||||
Interest (income) - adjustment | ---- | -226.74%-193.26M | ---- | -16.78%-59.15M | ---- | -40.01%-50.65M | ---- | 37.83%-36.17M | ---- | -139.28%-58.19M |
Impairment and provisions: | ---- | 133.24%284.47M | ---- | 656.67%121.96M | ---- | 77.90%-21.91M | ---- | -80.66%-99.14M | ---- | 27.43%-54.88M |
-Impairment of property, plant and equipment (reversal) | ---- | -80.61%4.15M | ---- | --21.39M | ---- | ---- | ---- | ---- | ---- | ---- |
-Impairmen of inventory (reversal) | ---- | 311.04%54.97M | ---- | 154.94%13.37M | ---- | 2.38%-24.34M | ---- | -9.39%-24.94M | ---- | 73.49%-22.8M |
-Impairment of trade receivables (reversal) | ---- | 150.61%214.63M | ---- | 3,322.08%85.64M | ---- | 96.34%-2.66M | ---- | -32.67%-72.52M | ---- | -712.08%-54.67M |
-Other impairments and provisions | ---- | 591.23%10.72M | ---- | -69.53%1.55M | ---- | 402.86%5.09M | ---- | -107.44%-1.68M | ---- | 1,484.70%22.58M |
Revaluation surplus: | ---- | 43.49%-75.84M | ---- | 24.00%-134.2M | ---- | 3.22%-176.57M | ---- | -118.90%-182.44M | ---- | -167.36%-83.34M |
-Other fair value changes | ---- | 43.49%-75.84M | ---- | 24.00%-134.2M | ---- | 3.22%-176.57M | ---- | -118.90%-182.44M | ---- | -167.36%-83.34M |
Asset sale loss (gain): | ---- | 512.54%15.43M | ---- | 97.82%-3.74M | ---- | -57,328.43%-171.71M | ---- | 94.24%-299K | ---- | -328.43%-5.19M |
-Loss (gain) from sale of subsidiary company | ---- | ---- | ---- | ---- | ---- | ---172.41M | ---- | ---- | ---- | ---- |
-Loss (gain) on sale of property, machinery and equipment | ---- | 512.54%15.43M | ---- | -639.05%-3.74M | ---- | 332.11%694K | ---- | 94.24%-299K | ---- | -184.57%-5.19M |
Depreciation and amortization: | ---- | 79.57%525.32M | ---- | 17.56%292.54M | ---- | -0.08%248.86M | ---- | -0.18%249.05M | ---- | 11.23%249.48M |
-Depreciation | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 6.26%223.51M |
-Amortization of intangible assets | ---- | 4,341.25%84.74M | ---- | 100.00%1.91M | ---- | --954K | ---- | ---- | ---- | ---- |
Financial expense | ---- | 20.04%158.41M | ---- | 10.28%131.97M | ---- | -9.54%119.67M | ---- | 54.77%132.28M | ---- | 369.12%85.47M |
Special items | ---- | -25.76%-279.58M | ---- | 19.65%-222.32M | ---- | -47.30%-276.71M | ---- | 30.15%-187.86M | ---- | -50.31%-268.95M |
Operating profit before the change of operating capital | ---- | 31.61%2.7B | ---- | 84.67%2.05B | ---- | 4.07%1.11B | ---- | 14.08%1.07B | ---- | 41.36%934.13M |
Change of operating capital | ||||||||||
Inventory (increase) decrease | ---- | 163.47%487.08M | ---- | -12.30%-767.4M | ---- | -91.10%-683.37M | ---- | -338.44%-357.59M | ---- | 174.29%149.97M |
Developing property (increase)decrease | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -6.54%-123.85M | ---- | ---116.25M |
Accounts receivable (increase)decrease | ---- | 60.98%-1.09B | ---- | -93.26%-2.79B | ---- | -60.51%-1.44B | ---- | -107.04%-899.22M | ---- | 49.08%-434.32M |
Accounts payable increase (decrease) | ---- | -99.48%11.6M | ---- | -5.06%2.24B | ---- | 73.94%2.36B | ---- | 1,217.90%1.36B | ---- | -87.15%102.86M |
prepayments (increase)decrease | ---- | 122.09%30.93M | ---- | 10.76%-139.97M | ---- | -959.83%-156.85M | ---- | -60.14%18.24M | ---- | 138.45%45.77M |
Special items for working capital changes | ---- | 11.86%684.05M | ---- | 868.20%611.51M | ---- | -213.34%-79.6M | ---- | -66.33%70.23M | ---- | 70.83%208.57M |
Adjustment items for working capital changes | ---- | ---- | ---- | ---1K | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from business operations | ---- | 134.82%2.82B | ---- | 8.83%1.2B | ---- | -2.25%1.1B | ---- | 26.76%1.13B | ---- | 117.61%890.74M |
China income tax paid | ---- | -197.26%-430.5M | ---- | 21.54%-144.83M | ---- | -70.57%-184.58M | ---- | -8.75%-108.21M | ---- | 27.42%-99.51M |
Interest received - operating | ---- | 229.50%150.98M | ---- | 120.92%45.82M | ---- | -64.81%20.74M | ---- | 276.80%58.95M | ---- | 70.86%15.64M |
Interest paid - operating | ---- | 3.77%-17.09M | ---- | -4.10%-17.76M | ---- | -80.95%-17.06M | ---- | -62.94%-9.43M | ---- | -514.12%-5.79M |
Special items of business | -115.53%-152.95M | ---- | 893.33%985.14M | ---- | -88.14%99.18M | ---- | 28.88%835.94M | ---- | 25.77%648.6M | ---- |
Adjustment items of business operations | ---- | ---- | ---- | --1K | ---- | ---- | ---- | ---- | ---- | ---- |
Net cash from operations | -115.53%-152.95M | 132.75%2.52B | 893.33%985.14M | 17.52%1.08B | -88.14%99.18M | -13.79%922.8M | 28.88%835.94M | 33.62%1.07B | 25.77%648.6M | 185.65%801.09M |
Cash flow from investment activities | ||||||||||
Interest received - investment | 79.12%25.06M | 145.55%41.21M | --13.99M | 133.01%16.78M | ---- | -48.99%7.2M | -76.21%2.01M | -49.81%14.12M | 363.84%8.47M | 136.33%28.14M |
Dividend received - investment | --58.26M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | -50.00%100M | -190.00%-180M | 300.00%200M | 166.67%200M | 50.00%-100M |
Decrease in deposits (increase) | 97.56%-1.27M | 123.85%6.99M | -414.38%-52.17M | -42.58%-29.29M | 3,555.07%16.59M | -1,421.03%-20.54M | 101.60%454K | -95.11%1.56M | -187.82%-28.45M | 272.21%31.8M |
Sale of fixed assets | -32.61%12.48M | -89.04%26.29M | 142.87%18.52M | 342.08%239.84M | 186.73%7.63M | -1.20%54.25M | -82.54%2.66M | 2.32%54.91M | 90.00%15.24M | 6.82%53.67M |
Purchase of fixed assets | 58.43%-404.97M | -105.44%-2.32B | -184.29%-974.13M | -20.23%-1.13B | 40.43%-342.65M | -141.27%-939.23M | -433.65%-575.25M | -44.51%-389.29M | 19.83%-107.79M | -87.46%-269.39M |
Purchase of intangible assets | -291.19%-61.39M | ---43.57M | ---15.69M | ---- | ---- | ---- | ---- | ---3.86M | ---3.86M | ---- |
Sale of subsidiaries | ---14.28M | ---- | ---- | ---- | ---- | -100.01%-3K | ---3K | --40M | ---- | ---- |
Acquisition of subsidiaries | -100.14%-650K | ---2.51B | --470.98M | ---- | ---- | ---17.82M | ---17.82M | ---- | ---- | ---- |
Recovery of cash from investments | -37.76%900.07M | -55.33%2.45B | -52.75%1.45B | -39.48%5.48B | -32.51%3.06B | 98.99%9.06B | 208.77%4.53B | -49.17%4.55B | -51.92%1.47B | 121.14%8.96B |
Cash on investment | 48.93%-860.05M | 33.64%-2.62B | 38.61%-1.68B | 53.84%-3.94B | 24.95%-2.74B | -66.87%-8.54B | -33.75%-3.66B | 53.53%-5.12B | 14.16%-2.73B | -158.70%-11.01B |
Net cash from investment operations | 55.35%-346.73M | -876.72%-4.97B | -65,099.92%-776.53M | 315.95%639.25M | -101.07%-1.19M | 54.27%-296.01M | 109.47%111.76M | 71.98%-647.37M | -126.54%-1.18B | -331.41%-2.31B |
Net cash before financing | -339.53%-499.68M | -241.62%-2.44B | 112.90%208.61M | 175.00%1.72B | -89.66%97.99M | 48.17%626.79M | 278.17%947.7M | 128.02%423.01M | -9,729.90%-531.9M | -491.62%-1.51B |
Cash flow from financing activities | ||||||||||
New borrowing | 110.99%5.89B | 84.72%7.07B | 89.72%2.79B | 0.42%3.83B | -35.63%1.47B | 35.60%3.81B | 14.73%2.28B | -24.96%2.81B | 117.37%1.99B | 247.38%3.75B |
Refund | -934.16%-3.83B | 7.93%-3.35B | 59.69%-370.11M | -21.46%-3.64B | 44.09%-918.1M | 12.51%-3B | -53.08%-1.64B | -81.55%-3.42B | -33.75%-1.07B | -1,614.50%-1.89B |
Issuing shares | -94.30%3.65M | 1,149.22%103.95M | 1,294.40%63.95M | -68.57%8.32M | -73.38%4.59M | -11.14%26.47M | 30.69%17.23M | -57.42%29.79M | -80.43%13.18M | --69.97M |
Issuance of bonds | ---- | ---- | ---- | ---- | ---- | ---- | ---500M | ---- | ---- | ---- |
Interest paid - financing | -42.75%-86.72M | -11.87%-126.28M | 1.85%-60.75M | -1.28%-112.88M | -22.64%-61.9M | 1.93%-111.46M | 26.84%-50.47M | -43.84%-113.66M | -99.50%-68.98M | -378.31%-79.02M |
Dividends paid - financing | -10.58%-217.55M | -56.33%-728.79M | -24.28%-196.73M | -3.43%-466.19M | -4.58%-158.3M | -14.38%-450.72M | 61.59%-151.36M | -22.67%-394.05M | -22.67%-394.05M | 27.02%-321.22M |
Absorb investment income | ---- | ---- | ---- | 216.67%13.3M | --13.3M | --4.2M | ---- | ---- | ---- | ---- |
Other items of the financing business | ---- | 87.08%-1.11M | 106.62%567K | 98.33%-8.56M | -58.33%-8.56M | -203.86%-511.48M | ---5.41M | --492.45M | ---- | ---- |
Net cash from financing operations | -22.08%1.73B | 885.69%2.96B | 551.53%2.23B | -66.22%-376.81M | 816.64%341.56M | 62.32%-226.7M | -110.21%-47.66M | -139.42%-601.72M | 365.05%466.88M | 198.34%1.53B |
Effect of rate | -103.57%-3.55M | 598.21%31.78M | 656.28%99.27M | -181.81%-6.38M | -308.91%-17.85M | -54.13%7.8M | 377.74%8.54M | 4.40%17M | -92.04%1.79M | 1,433.42%16.28M |
Net Cash | -49.29%1.23B | -61.43%519.47M | 453.75%2.43B | 236.65%1.35B | -51.16%439.55M | 323.87%400.09M | 1,484.26%900.04M | -1,152.27%-178.72M | 64.19%-65.02M | -93.38%16.98M |
Begining period cash | 20.49%3.24B | 99.34%2.69B | 99.34%2.69B | 43.32%1.35B | 43.32%1.35B | -14.66%941.45M | -14.66%941.45M | 3.11%1.1B | 3.11%1.1B | 31.34%1.07B |
Cash at the end | -14.38%4.47B | 20.49%3.24B | 194.92%5.22B | 99.34%2.69B | -4.27%1.77B | 43.32%1.35B | 77.90%1.85B | -14.66%941.45M | 14.18%1.04B | 3.11%1.1B |
Cash balance analysis | ||||||||||
Cash and bank balance | ---- | ---- | ---- | ---- | ---- | ---- | --1.85B | ---- | ---- | ---- |
Cash and cash equivalent balance | ---- | ---- | ---- | ---- | ---- | ---- | 77.90%1.85B | ---- | 14.18%1.04B | ---- |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.